MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation.
Moonlake Immunotherapeutics stock last closed at $17.75, down 1.5% from the previous day, and has decreased 53.76% in one year. It has underperformed other stocks in the Biotechnology industry by 0.21 percentage points. Moonlake Immunotherapeutics stock is currently +198.32% from its 52-week low of $5.95, and -71.71% from its 52-week high of $62.75.
As of Mar 26, 2026, there are 71.73M shares of MLTX outstanding. The market capitalization of MLTX is $1.27B. In the last 24 hours, 1.35M MLTX shares were traded.
How to Buy Moonlake Immunotherapeutics Stock
Wondering how to invest in Moonlake Immunotherapeutics stock? Here's how.
Figure out where to buy Moonlake Immunotherapeutics stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Moonlake Immunotherapeutics stock.
Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Fund your brokerage account: Pick your payment method and add your details.
Analyze Moonlake Immunotherapeutics stock: The Moonlake Immunotherapeutics ticker symbol is MLTX. Is Moonlake Immunotherapeutics stock a good investment? Should you buy shares of MLTX? How do MLTX's underlying business fundamentals look? Do top analysts think Moonlake Immunotherapeutics is a good buy? Why has MLTX's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if MLTX is a good stock to buy).
Place your MLTX buy order: Decide if you will purchase MLTX shares at the current market price or use a limit order to purchase MLTX shares at a particular price.
Get the latest news on your MLTX position: Create a watchlist to important notifications about your position in Moonlake Immunotherapeutics stock.
Step 1: Figure out where to buy Moonlake Immunotherapeutics stock
You will need an online brokerage account in order to access the NASDAQ market and buy MLTX stock.
A brokerage account is an investment account that allows you to buy and sell a number of investments, including stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
In our opinion, eToro is the best brokerage. Here's why:
Invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to world markets: From Tech to Industrials, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal details so you are able to buy MLTX today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Moonlake Immunotherapeutics stock
After you have chosen the best place to buy Moonlake Immunotherapeutics stock, it's crucial to analyze their stock before you buy, so you can comprehend the risk as well as the upside.
Moonlake Immunotherapeutics Numbers
MLTX Price
$17.75
1w %
6.41%
1y %
-53.76%
5y %
74.77%
P/E
-5.03x
P/B
4.18x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$230.32M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$1.27B
Next Earnings
N/A
Next Dividend
N/A
Moonlake Immunotherapeutics Due Diligence Checks
WallStreetZen was built to help everyday investors perform better fundamental analysis.
Total MLTX debt is lower than 5 years ago, relative to shareholder equity.
MLTX has a low debt to equity ratio of 0.39.
There are more short-term assets than short-term liabilities on the MLTX balance sheet.
MLTX has cash burn of 196042000. It has enough cash and short-term investments to cover this for at least one year.
There are more short-term assets than long-term liabilities on the MLTX balance sheet.
Failed Financial Due Diligence Checks:
MLTX has $393.97M in cash and short term investments. This is not enough to cover its annual cash burn of $196.04M.
Is it a good time to buy MLTX stock, according to analysts?
Out of 12 sell side analysts who track MLTX, the consensus analyst rating on Moonlake Immunotherapeutics is a Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
Most Recent MLTX Analyst Recommendations
Serge Belanger, a top 1% analyst from Needham reiterates MLTX with a buy rating and maintains their MLTX price target from $25.00 to $25.00, on Feb 26, 2026.
Andreas Argyrides, a top 8% analyst from Oppenheimer maintains MLTX with a buy rating and raises their MLTX price target from $30.00 to $35.00, on Feb 24, 2026.
Julian Harrison, a top 3% analyst from BTIG maintains MLTX with a strong buy rating and raises their MLTX price target from $24.00 to $30.00, on Feb 23, 2026.
Richard Law, a top 17% analyst from Goldman Sachs downgrades MLTX to a strong sell rating and raises their MLTX price target from $8.00 to $10.00, on Jan 15, 2026.
Samantha Semenkow, a bottom 13% analyst from Citigroup downgrades MLTX to a strong sell rating and maintains their MLTX price target from $5.00 to $5.00, on Oct 29, 2025.
No, Moonlake Immunotherapeutics doesn't provide an income stream by paying out dividends.
What others are saying about MLTX
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your MLTX buy order
You have two main options:
Market order: A market order is an order to buy or sell a security at the best price on the market. Market orders are mostly fine for most investors.
Limit order: A limit order enables you to buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at a given price, place a limit order.
Hit the Open Trade button and your broker will execute your order.
If you require more help with buying stocks on eToro, watch the helpful video below:
How much does it cost to buy one Moonlake Immunotherapeutics share?
As of Mar 26, 2026, it costs $17.75 to buy one share of Moonlake Immunotherapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $8, you can buy 0.451 shares of MLTX.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Is now a good time to buy Moonlake Immunotherapeutics stock?
According to 12 Wall Street analysts who monitor Moonlake Immunotherapeutics, their consensus recommendation is to buy Moonlake Immunotherapeutics stock.
What is the best way to buy Moonlake Immunotherapeutics stock?
One way to place an order for Moonlake Immunotherapeutics stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.